RECRUITING

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Talk to us

Conditions

Localized Renal Pelvis and Ureter Urothelial CarcinomaMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Soft TissuesMetastatic Renal Pelvis and Ureter Urothelial CarcinomaRecurrent Bladder CarcinomaRecurrent Prostate CarcinomaRecurrent Renal Pelvis and Ureter Urothelial CarcinomaStage IV Bladder Cancer AJCC v7Stage IV Bladder Urothelial Carcinoma AJCC v7Stage IV Prostate Cancer AJCC v7

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder/urothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.

Official Title

Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

Quick Facts

Study Start:2009-08
Study Completion:2029-01-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01050504

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with localized and/or metastatic bladder/urothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured
  2. * Ability to adequately understand and give informed consent
  3. * Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications Or the ability to obtain tissue with minimal risk of complication from a surgical procedure being conducted as a part of another research study Or for standard of care purposes or patients who have archival tissue collected for research or standard of care who are willing to donate archival tissue for this study
  4. * Alternatively, men and women without cancer or who are at risk of developing cancer are eligible to have blood or normal tissue collected if acquired; tissue will only be acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder; in patients without malignancy, no additional tissue beyond that necessary for care will be procured
  5. * Platelet count \> 50,000
  6. * White blood cell (WBC) \> 1,500
  7. * Hemoglobin (Hgb) \> 8.0
  8. * International normalized ratio (INR) \< 1.5
  9. * Partial thromboplastin time (PTT) \< 45
  10. * No history of excessive unexplained bleeding from previous surgery
  1. * Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days
  2. * Serious or uncontrolled infection
  3. * Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days

Contacts and Locations

Study Contact

Robert B. Montgomery
CONTACT
206-598-0856
rbmontgo@uw.edu

Principal Investigator

Robert B. Montgomery
PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium

Study Locations (Sites)

Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: University of Washington

  • Robert B. Montgomery, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2009-08
Study Completion Date2029-01-31

Study Record Updates

Study Start Date2009-08
Study Completion Date2029-01-31

Terms related to this study

Additional Relevant MeSH Terms

  • Localized Renal Pelvis and Ureter Urothelial Carcinoma
  • Malignant Solid Neoplasm
  • Metastatic Malignant Neoplasm in the Bone
  • Metastatic Malignant Neoplasm in the Soft Tissues
  • Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
  • Recurrent Bladder Carcinoma
  • Recurrent Prostate Carcinoma
  • Recurrent Renal Pelvis and Ureter Urothelial Carcinoma
  • Stage IV Bladder Cancer AJCC v7
  • Stage IV Bladder Urothelial Carcinoma AJCC v7
  • Stage IV Prostate Cancer AJCC v7